Penzberg, Germany

Markus Horvath

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Markus Horvath

Introduction

Markus Horvath is a notable inventor based in Penzberg, Germany. He has made significant contributions to the field of biotechnology, particularly through his innovative methods in cellular biology. His work has led to advancements that are crucial for various applications in medical research.

Latest Patents

One of Markus Horvath's key patents is titled "Method for the production of thymocyte supernatant." This patent describes a method for producing a thymocyte supernatant by co-cultivating thymocytes and mononuclear cells at a cell ratio of at least 0.5:1.2. The process involves the presence of phorbol-12-myristate-13-acetate and Phytohemagglutinin M for up to 60 hours, followed by the separation of the co-cultivation medium from the cells, resulting in the production of the thymocyte supernatant. This innovative method has the potential to enhance research in immunology and related fields.

Career Highlights

Throughout his career, Markus Horvath has worked with prominent companies in the pharmaceutical industry, including Hoffmann-La Roche Inc. and F. Hoffmann-La Roche AG. His experience in these organizations has allowed him to collaborate with leading experts and contribute to groundbreaking research and development projects.

Collaborations

Markus has collaborated with several talented individuals in his field, including Sonja Offner and Ingried Saam. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Markus Horvath's contributions to the field of biotechnology, particularly through his patent on thymocyte supernatant production, highlight his role as an influential inventor. His work continues to impact medical research and the development of new therapeutic approaches.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…